

Biocytogen signs RenMab/RenLite licensing agreement with BeiGene

11 April 2022 | News

RenMab and RenLite was developed by Biocytogen over 5 years using SUPCE, a size-unlimited, precise chromosome engineering technology



Biocytogen Pharmaceuticals (Beijing) Co., Ltd. have reached an agreement with BeiGene (Beijing) for licensing of Biocytogen's fully human antibody RenMab/RenLite mice platform with proprietary intellectual property rights of Biocytogen to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.

RenMab and RenLite was developed by Biocytogen over 5 years using SUPCE, a size-unlimited, precise chromosome engineering technology. In RenMab mice, the whole mouse variable regions of the heavy and kappa light chains were replaced by full human heavy chain VDJ segment and light chain VJ loci *in situ*; In RenLite mice, the whole mouse variable regions of the heavy chain were replaced with full human heavy chain VDJ segment *in situ*, and the whole mouse variable regions of the λ light chain was replaced with a single human λ light chain VJ loci *in situ*. RenMab/RenLite mice can generate fully human antibody candidates with high affinity, specificity, and diversity for downstream antibody drug screening. Meanwhile, the common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies.